Pharm Exec's latest annual listing of the top biopharma players paints a stable picture of performance for the usual placeholders, but change and disruption to current business models could upend positioning in the years ahead.
Advanced Gene & Cell Technologies (AGCT), a resident startup of the Skolkovo Foundation’s biomed cluster, has received the first tranche of investment from the RBV Capital venture fund allocated to carry out Russia’s first clinical practice of genome editing to treat HIV. AGCT plans to use the investment, which totals 44 million rubles ($738,000), to draw up a raft of preclinical data to carry out pilot phase one and two clinical research.
Medical professor Christopher Rudd and his research team have identified a key new mechanism that regulates the ability of T-cells of the immune system to react against foreign antigens and cancer.
The Department of Justice on Thursday announced what Attorney General Jeff Sessions called the "largest healthcare fraud takedown operation in American history."
By working with inner Justice Department offices and the Department of Health and Human Services, the federal government charged 412 defendants accused of defrauding taxpayers of roughly $1.3 billion. The charges included 56 doctors, Session said.